Irinotecan Hcl Aqvida Gmbh (Irinotecan Hydrochloride)

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hcl Aqvida Gmbh, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients. GNH USA supplies Irinotecan Hcl Aqvida Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Hydrochloride is a chemotherapy agent used primarily in the colorectal cancer treatment pathway.

Metastatic colorectal cancer: improves survival outcomes when incorporated into standard combination chemotherapy regimens.

Irinotecan Hydrochloride may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea (often early‑onset) - Neutropenia - Fatigue - Alopecia - Mild abdominal cramping

Serious or Rare Side Effects: - Severe (late‑onset) diarrhea and colitis - Febrile neutropenia - Hepatic toxicity